Clearside Biomedical to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update on Thursday, March 10, 2022

Rhea-AI Summary

Clearside Biomedical (NASDAQ:CLSD) will report its fourth quarter and full year 2021 financial results on March 10, 2022, post-market. A conference call and webcast will follow at 4:30 PM ET for discussion and corporate updates. Clearside is known for its innovative suprachoroidal space (SCS) technology that enhances therapy delivery to the eye. Their first product, XIPERE™, was FDA-approved in October 2021, marking a significant advancement in vision-preserving treatments.

Positive

• FDA approval of XIPERE™ in October 2021.

Negative

• None.

ALPHARETTA, Ga., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS^®), announced today that its fourth quarter and full year 2021 financial results will be reported on Thursday, March 10, 2022 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. The live call can be accessed by dialing (844) 263-8310 (domestic) or (213) 358-0959 (international) and entering conference code: 6354534. An archive of the webcast will be available for three months.

About Clearside Biomedical

Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS^®). Clearside’s SCS injection platform, utilizing the Company’s proprietary SCS Microinjector^®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector and strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. Clearside’s first product, XIPERE^™ (triamcinolone acetonide injectable suspension) for suprachoroidal use, was approved by the U.S. Food and Drug Administration in October 2021. For more information, please visit www.clearsidebio.com.

Investor and Media Contacts:

Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
(678) 430-8206

Source: Clearside Biomedical, Inc.

FAQ

When will Clearside Biomedical announce its fourth quarter 2021 financial results?

Clearside Biomedical will announce its fourth quarter and full year 2021 financial results on March 10, 2022.

What is the significance of the FDA approval for Clearside's product?

The FDA approval of XIPERE™ in October 2021 represents a critical milestone for Clearside, enabling them to market their innovative therapy for eye diseases.

How can investors access the Clearside Biomedical earnings call?

Investors can access the earnings call by dialing (844) 263-8310 for domestic calls or (213) 358-0959 for international calls, using conference code 6354534.

What technology does Clearside Biomedical utilize for eye therapies?

Clearside Biomedical utilizes its proprietary suprachoroidal space (SCS) technology to deliver therapies directly to the back of the eye.